Vacciguard Novel Vaccines

Vacciguard novel vaccines

 

HSP-60 peptide conjugates convert a weak antigen into a strong immunogen
Advantages of VacciGuard's Technology Print E-mail

VacciGuard's vaccine technology has the following advantages over the existing vaccine technologies:

  • The conjugated vaccines act as natural/endogenous adjuvants. Therefore there is no need for an external adjuvant with its associated side-effects.

  • The carriers, HSP-60-derived peptides, are relatively short and do not induce the production of neutralizing antibodies. Therefore, no "carrier-induced epitope suppression" phenomena are elicited. This contrasts with carriers such as the tetanus toxoid, cholera toxin or diphteria toxoid.

  • HSP-60 derived peptides are universal T cell epitopes and therefore enhance the T cell function, supporting the generation of long-lasting memory (formation of IgG antibodies by B cells).

  • The conjugated vaccines are relatively stable and easy to store.


Vaccine Type Immunogenicity Adjuvant Safety Long-term Efficacy Storage, Stability
VacciGuard +++ Not needed +++ +++ +++
Attenuated pathogens +++ Needed + +++ +
Subunits + Needed +++ + +++
Conjugated subunits ++ Needed ++ ++ +++

Back
 
<< Start < Prev 1 2 3 Next > End >>

Page 3 of 3

 

 

A scientist wearing protective gloves works with cell culture